Stem Cell Clinical Trial for Multiple Sclerosis Approved by FDA

Posted: Published on November 23rd, 2013

This post was added by Dr. Richardson

Oct 04, 2013

The Tisch MS Research Center of New York announced on August 14 that the FDA has given its approval to begin a clinical trial to use stem cells in the treatment of multiple sclerosis.

Approximately 2.1 million people worldwide are affected by multiple sclerosis, a degenerative autoimmune disease that affects the nervous system and leads to myelin damage. According to Dr. Saud A. Sadiq, senior research scientist at Tisch, this is possibly the first effort in the U.S. that will investigate treatment of MS through direct injection of stem cells into the spinal fluid of patients. He says that the effort represents an exciting advance in MS research and treatment.

The Tisch MS Research Center is a unique organization with a novel approach to the treatment of multiple sclerosis. Dr. Sadiq has believed for over two decades that combining high standards of clinical care with research targeted at finding the cure to MS would improve the overall standard of treatment for MS patients. In short, at the Tisch center, your researcher is your doctor.

This is different from the standard model, where researchers spend the majority of their time conducting studies, trials, and lab work, while doctors apply the results of research in treating patients. By combining the two and allowing the doctor to conduct research tailored specifically to his patient, the center increases the pace at which discoveries can make it from lab to practice. This recent approval is evidence of the success of Dr. Sadiqs philosophy.

The study in question will use stem cells harvested from the subjects own bone marrow. Patients will undergo a single bone marrow collection. From there, the appropriate stem cells will be isolated and extracted, then tested before they are injected into the patient. Once this is complete, the cells will then be injected into the fluid surrounding the patients spinal cord, which early tests indicate will decrease inflammation in the brain and promote repair of CNS myelin, a protein-rich substance that is necessary for healthy nervous system functioning, and a substance which multiple sclerosis causes the body to attack and destroy.

Read more here:
Stem Cell Clinical Trial for Multiple Sclerosis Approved by FDA

Related Posts
This entry was posted in FDA Stem Cell Trials. Bookmark the permalink.

Comments are closed.